Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd - Investor Relations & Filings

Listed IPO Mar 2011
Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,017 across all filing types
Latest filing 2025-12-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194 · 1 venue

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving a drug registration certificate from a regulatory authority (国家药品监督管理局). It provides details about the drug, its approval, and potential market impact. The document is short (662 characters) and serves as an official notification rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed regulatory filings. It is an announcement of a regulatory event related to product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-10 Chinese
关于公司产品纳入《国家医保药品目录》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a product into the National Medical Insurance Drug Catalog, issued by the company's board. It contains no financial statements or detailed financial data, nor does it announce voting results or management changes. It is a regulatory announcement about product listing and its potential impact on sales, which does not fit into categories like Annual Report, Earnings Release, or Capital Update. The document is short (605 characters) and is an official disclosure to investors about a regulatory update affecting the company. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-12-08 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving a drug registration certificate from the national drug regulatory authority. It details the drug name, registration classification, specifications, approval number, and regulatory conclusion. The content is an official announcement of a regulatory approval event, not a financial report, management change, or shareholder meeting material. It does not contain financial data, earnings information, or governance details. It is a regulatory announcement related to product registration and market impact risks. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-12-01 Chinese
关于子公司收到菲律宾GMP符合性证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary receiving a GMP compliance certificate from the Philippine health authority. It includes details about the certificate, the scope of certification, and potential impacts on overseas market expansion. The document is short (1054 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory or compliance milestone rather than a financial report or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-11-05 Chinese
关于子公司参与全国药品集中采购拟中选的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding its subsidiaries' participation and tentative selection in a national centralized drug procurement process. It details the products proposed for selection, their sales data, pricing, and potential impact on the company. The document is an official announcement of a business event related to procurement results, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial analysis. The document length is 2648 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous official announcements that do not fit other categories.
2025-10-28 Chinese
关于为子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing guarantees for bank financing applied for by its subsidiaries. It includes details about the guarantee amounts, the subsidiaries involved, their financial data, and board approval. The document is relatively short (2492 characters) and focuses on a specific financing guarantee event rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report or Annual Report. It is not a certification or officer attestation. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company for credit facilities.
2025-10-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.